Creation of viral growth inhibitors targeting SARS-CoV-2 protease

Grant number: 21K07050

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2024
  • Known Financial Commitments (USD)

    $37,440
  • Funder

    KAKENHI
  • Principal Investigator

    Hoshino Tadashi Hoshino
  • Research Location

    Japan
  • Lead Research Institution

    Chiba University
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Development of Inhibitory Compounds for Metallo-beta-lactamase through Computational Design and Crystallographic Analysis.

Sticklac-Derived Natural Compounds Inhibiting RNase H Activity of HIV-1 Reverse Transcriptase.

Computational and Crystallographic Analysis of Binding Structures of Inhibitory Compounds for HIV-1 RNase H Activity.

Quantifying the Separation of Positive and Negative Areas in Electrostatic Potential for Predicting Feasibility of Ammonium Sulfate for Protein Crystallization.

Secondary Structure and Conformational Stability of the Antigen Residues Making Contact with Antibodies.